Botulinum toxin A injection - Revance Therapeutics

Drug Profile

Botulinum toxin A injection - Revance Therapeutics

Alternative Names: DaxibotulinumtoxinA Injection; RT-002

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator Revance Therapeutics
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Acetylcholinesterase inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines
  • Phase II Plantar fasciitis; Torticollis
  • No development reported Skin disorders

Most Recent Events

  • 18 May 2017 Interim efficacy and adverse events data from phase II trial in Torticollis released by Revance Therapeutics
  • 01 May 2017 Revance Therapeutics initiates enrolment in a phase II trial for Plantar fasciitis in USA (NCT03137407)
  • 07 Mar 2017 Revance Therapeutics completes enrolment in its phase III trial for Glabellar lines in USA and Cananda (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top